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In phase III cancer clinical trials, overall survival is commonly used as the definitive endpoint.  
In phase II clinical trials, however, more immediate endpoints are generally used such as 
incidence of complete or partial response within one or two months or progression-free survival 
(PFS).  Due to the limited ability to detect change in overall survival with response, the inherent 
variability of PFS and the long wait for progression to be observed, more informative and 
immediate alternatives to overall survival are desirable in exploratory phase II trials. In this 
paper we show how comparative trials can be designed and analysed using change in tumour size 
as the primary endpoint.  The test developed is based on the framework of score statistics and 
will formally incorporate the information of whether patients survive until the time at which 
change in tumour size is assessed.  Using an example in non-small cell lung cancer, we show that 
the sample size requirements for a trial based on change in tumour size are favourable compared 




In confirmatory clinical trials in cancer, overall survival (OS) is commonly used as the definitive 
endpoint.  In early phase trials of cancers involving solid tumours, more immediate measures of 
tumour shrinkage such as incidence of complete or partial response within one or two months or 
progression-free survival (PFS) are used.  Each of these endpoints has been criticised for 
different shortcomings. The value of tumour response has been questioned for drugs acting to 
stabilize tumour size and more generally after several instances where high response rates did not 
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translate into improved survival [1].  PFS on the other hand suffers from the long wait for 
progression to be observed and is heavily influenced by the assessment schedules [2]. 
Consequently more informative and immediate endpoints capable of predicting overall survival 
are desirable in exploratory (Phase II) trials. 
 
A natural alternative to the endpoints above is to use the tumour size itself as the primary 
endpoint in the early stages of development.  The RECIST guideline [3,4] recommends the use 
of the sum of the largest diameters of solid tumours as a measurement of the size of a tumour 
while various authors have, for different types of cancer, shown that tumour size is related to 
survival [5, 6].  Moreover it has been conjectured that change in tumour size can be used to aid 
decisions about proceeding to a confirmatory trial in non-small cell lung cancer [7] and 
approaches for designing and analysing trials using continuous tumour size measurements have 
been discussed [8,9]. More recently it has been demonstrated that using tumour size in 2-stage 
single armed cancer trials can reduce the required sample size by approximately one third [10]. It 
is important to note here that to determine tumour response or PFS, the tumour size has to be 
measured anyway. Using tumour size as primary endpoint does therefore not require any 
additional data to be collected beyond what is currently recorded.  
 
In this manuscript we derive the methodology necessary to design and analyse a comparative 
trial based on change in tumour size (Section 2). The method is based on score statistics and, 
unlike previous work [8-10], formally incorporates whether a patient survives until the time of 
tumour size assessment.  The methodology is constructed so that the effect on change in tumour 
size is a function of the treatment effect in terms of overall survival, and particular focus will be 
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given to designing such a trial.  In Section 3 we compare the sample size requirements for 
different early phase cancer trial design alternatives in the context of a trial in non-small cell lung 
cancer.  We relate the effects of treatment on change in tumour size and on PFS to the treatment 
effect on OS, using pre-existing data in which all of these measures are available to ensure a fair 
comparison between the methods. A thorough sensitivity analysis is included to evaluate the 
robustness of the sample size comparison. The manuscript concludes with a brief discussion and 
further directions. 
 
2. Designing and analysing trials based on change in tumour size 
For a trial based on change in tumour size, the extent of the tumour is measured immediately 
prior to treatment at time t0, and after start of the treatment at time, t1 (often one or two months 
later). The analysis of such a trial then comprises of two separate components: surviving until 
time t1 (yes or no) and the change in tumour size for patients who survived until t1. To establish 
whether a novel treatment yields an improvement over control we will model the treatment 
difference in respect of both components using a single parameter.  To do so we require historical 
data on both tumour size and survival for each patient. As the dataset is used to relate both 
endpoints to overall survival the patients in this dataset should have received the same treatment 
as the control group of the forthcoming phase II study.  As pointed out above, tumour size is 
currently collected in most phase II cancer trials as it is used to determine both tumour response 
and PFS, while survival time is a standard secondary endpoint in these studies. As a result a 
suitable historical dataset will often be available. 
 
After the study has been completed, the following data are available for the ith patient: xi – 
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treatment indicator, 0 for control treatment (C) and 1 for experimental treatment (E); zi – vector 
of prognostic factors (baseline tumour size, …); si – survival until t1, 1 for no and 0 for yes; di – 
change in tumour size, cts (missing if si = 0). We denote the vector of the treatment indicators for 
all subjects by x  (x1, …, xn) and similarly define s and d as the vectors of survival indicators 
and changes in tumour size, respectively. The matrix of prognostic factors will be written as z. 
Note further that patients dropping out of the study will be given a survival indicator of one (i.e 
treated as deaths). This is to ensure that the resulting treatment effect estimate is pessimistic 
rather than overly optimistic and is in line with the standard way of handling drop-outs in a trial 
based on response.  
 
The parameter expressing the difference between treatments in the proportions of patients dying 
before the second visit, θpsurv, can be estimated using a generalized linear model relating the si 
to xi and zi.  An estimate for the treatment effect on change in tumour size, θ̂cts, where θcts is the 
parameter expressing the difference in mean tumour size measurements, will be found using a 
linear regression model of di on xi and zi for all patients surviving until t1.  Specifically, θcts =
𝜇𝐸 − 𝜇𝐶 with µE and µC denoting the mean change in tumour size in the experimental and control 
group, respectively.  
 
For large enough samples, θ̂i~𝑁 {θi, 𝑠𝑒(θ̂i)
2
} for i = psurv, cts and θ̂psurv and θ̂cts are 
independent provided prognostic factors, z, have been accounted for in the estimation of the 
parameters.  This follows because the joint density of s and d satisfies: 
𝑓(𝒔, 𝒅|𝜷𝟏, 𝜷𝟐, 𝒙, 𝒛) = 𝑓1(𝒔|𝜷𝟏, 𝒙, 𝒛)𝑓2(𝒅|𝜷𝟐, 𝒔, 𝒙, 𝒛) 
where 1 are the parameters governing the generalized linear model of survival until t1 and 2 are 
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the parameters associated with the regression of changes in tumour size amongst the survivors. 
These two measures can now be put into the familiar framework of score tests by defining 
𝑍𝑖 = θ̂i/𝑠𝑒(θ̂i)
2  which for large n and small 𝜃𝑖 yields 𝑍𝑖~𝑁(θi𝑉𝑖, 𝑉𝑖), where 𝑉𝑖 = 1 {𝑠𝑒(𝜃𝑖)}
2
⁄  
is the information. 
 
In order to obtain a single test statistic that can be used to establish whether a novel treatment 
yields an improvement over control, the two score tests above need to be related to a single 
parameter.  As the objective of the treatment is to extend overall survival, this single parameter is 
taken to be θOS, the negative of the log hazard ratio in terms of overall survival.  
 
As pointed out above, an estimate of the effect for survival until time t1 can be obtained in terms 
of the log-odds ratio for a treated person relative to an untreated person by fitting a generalized 
linear model of si on xi and zi.  If the complementary log-log link is used in this model, then the 
survival parameter, θpsurv, defined as  
θpsurv = log{− log(1 − 𝑝𝐶)} − log {− log(1 − 𝑝𝐸)} 
where pC and pE are the proportions of subjects dying at time t1 on control and experimental 
treatment, respectively, is exactly equal to θOS, the log-hazard ratio for overall survival [11, 
Chapter 9].  Note that, even if the logit link is used this relationship holds approximately as pE 
and pC are typically small. Consequently we can write the distribution of the first score statistic 
as 𝑍psurv~𝑁(θOS𝑉psurv, 𝑉psurv). 
 
To find a similar relationship between overall survival and change in tumour size we use a Cox-
proportional hazards model of the form 
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h(t | 𝐳i, cts) = h0(t)e
𝛃′𝐳i+βcts×cts, t > t1 
where zi is the vector of covariates and β the vector of associated coefficients using the existing 
historical dataset. Note that βcts will be negative if a smaller tumour size corresponds to smaller 
hazard (see Eqn (2) below) and that the model will be based on only patients who survive to t1. 
Provided that there are no interactions between treatment and the prognostic factors in the model, 
the hazard functions of the two treatment groups, will be related via hE(t | 𝐳i, cts) =
𝑒−𝜃𝑂𝑆hC(t | 𝐳i, cts), where hE corresponds to the hazard function of the experimental group and 
hC to that of the control group.  A patient who would have a change in tumour size equal to cts if 
put on the control treatment, will therefore typically have change in tumour size of cts + cts if 
put onto experimental treatment.  It follows that, approximately, 
   hE(t | 𝐳i, cts) = h0(t)e
𝛃′𝐳i+βcts(cts+θcts) 
                        = eβctsθctshC(t | 𝐳i, cts). 
Note that in the above we are assuming that any treatment effect on overall survival (conditional 
on survival to t1) is captured by the effect of treatment on change in tumour size.  The change in 
tumour size parameter can therefore be expressed in terms of a hazard ratio for overall survival 
as 𝑒−𝜃𝑂𝑆 = eβctsθcts so that 
                                                                     θcts =
θOS
−βcts
.                                                                             (1)  






A natural choice to constructing the joint test statistic is then 







The division by −β
cts
 arises from the desire to construct a dimensionless test statistic, Q: 𝑍cts, 
carries forward the dimension of β
cts
 by construction resulting in different values of 𝑍cts if (for 
example) tumour size is measured in mm or in inches.  Moreover the distribution of the test 
statistic then has the familiar structure, 
𝑄~𝑁 {θOS (𝑉psurv +
1
βcts




The null hypothesis of no difference between control and experimental treatment is then rejected 
if Q exceeds the critical value u.  At the design stage, the critical value, u, and the sample size, n, 

















Using a R:1 randomization between experimental and control treatment and denoting the total 
sample size of the trial by n gives 𝑛𝐸 = 𝑅𝑛 (𝑅 + 1)⁄  and 𝑛𝐶 = 𝑛 (𝑅 + 1)⁄  which are the sample 
sizes of the experimental and control arm, respectively. Using the complementary log-log link 
the pair (Zpsurv, Vpsurv) can, for large n, be found as  
𝑍psurv =
𝑛𝑅𝑞
(𝑅 + 1)(?̂?𝐶 + 𝑅?̂?𝐸)





[e.g. 12, p. 42].  The quantity ?̂?𝐶 − ?̂?𝐸 is the change in proportion of patients dying before t1 on 
control versus experimental treatment, ?̅? is the average proportion of patients dying before t1 and 
𝑞 = −log (1 − ?̅?). Note that, although we have allowed for covariates when we derived the 
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relationship between survival and change in tumour size, the above expression does not include 
them.  When finding the relationship θcts = θOS (−βcts)⁄  based on existing historical dataset, 
inclusion of covariates ensures that the effect, θcts, can be estimated more precisely. When 
designing a new trial, however, the nature of the covariate structure of the dataset to be collected 
is unknown and hence proceeding without such a structure is sensible.  For the purpose of 
analysing a trial in which case covariate adjustment is likely to be of interest, expressions for 
Zpsurv and Vpsurv can be found for example in [12]. 
 
For the analysis of change in tumour size for patients surviving past t1 we assume that the change 
in tumour size measure is normally distributed with equal variance, σ2, in both arms. The 
parameter of interest can then be defined as θcts = 𝜇𝐸 − 𝜇𝐶 with µE and µC denoting the mean 
change in tumour size in the experimental and control group, respectively. The sampling 
distribution of the estimate obtained by taking the difference in sample means is then  




so that the corresponding score statistic, obtained without covariate adjustment for the purpose of 
designing the study, is Zcts = θ̂cts {𝑠𝑒(θ̂cts)}
2
⁄  , and the information is 𝑉cts = 𝑛𝑅 {𝜎
2(𝑅 + 1)2}⁄ . 












































3. Comparing sample size requirement for trials using different endpoints 
Having described how a trial based on tumour size can be designed and analysed, we now 
compare the sample size requirements of such a trial to alternative Phase II endpoints in the 
context of a particular therapeutic area. We focus on comparisons with trials based on tumour 
response and progression-free survival, and for completeness include some comparison with 
single-armed trials based only on tumour response.  
 
The main challenge in making the comparison is to ensure comparable sizes of treatment effect. 
As illustrated in Figure 1, we will anchor our comparisons around meaningful differences in 
overall survival which can be translated into the relevant effects for surviving to t1 and change in 
tumour size as described in the previous section. Then in Section 3.2 we analytically derive the 
effect size in terms of tumour response from these measures, while a proportional hazards model 
is used to relate PFS and change in tumour size.  
 
~~~ FIGURE 1 ~~~ 
 
Using the equivalent effect sizes, the various sample size requirements will be compared 
(Section 3.3) and the sensitivity to assumptions made when deriving equivalent effect sizes 





The following comparison is based upon a dataset of 288 patients with non-small cell lung 
cancer (NSCLC). The data are the control arm, receiving standard of care for NSCLC, of a recent 
randomized phase III trial. The dataset includes the main variables overall survival and 
progression-free survival as well as sum of the largest diameter of up to 10 lesions at the initial 
visit, S0, and after 8 weeks, S8,  defined according to RECIST 1.0 [3].   The change in tumour 
size for an individual patient is defined as 
cts = log{(1 + S0) (1 + S8⁄ )} = log(1 + S0) − log(1 + S8),    (2) 
being the shifted log-difference of tumour size.  This definition was chosen so that cts is positive 
for a positive outcome (i.e. a reduction in tumour size) and because the distribution of cts defined 
in this way was found to be approximately normal in the dataset studied.  The shift by 1 caters 
for patients with a tumour size of zero (complete response).  Note that the methods described in 
this paper are also applicable to other measures of change in tumour size, provided that they can 
be modelled as normally distributed, or for large sample sizes an asymptotic normal distribution 
can be assumed for the test statistic.  
 
The following covariates were included as prognostic factors in the models used to find 
equivalent effect sizes: sum of the largest diameter of up to 10 lesions at visit 0 (which will be 
referred to as baseline), ECOG-score [13] and gender.  Other variables such as age, though 
available, were not used in the models as they did not contribute significantly to their fit.  
Patients who had either an ECOG score greater than 1 or did not have a baseline tumour size 
measurement were excluded, leaving 225 patients for model building and relating effect sizes.    
 
3.2. Effect sizes 
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In Section 2 we discussed how effect sizes for change in tumour size based on a desired effect in 
terms of hazard ratio for overall survival can be found. In particular it was argued that the effect 
on surviving to 8 weeks is equivalent to the hazard ratio for overall survival, θOS, while the effect 
in change in tumour size is found to be θcts = θOS (−βcts)⁄ = θOS 2.2159⁄  in the dataset on 
NSCLC. A hazard ratio of 0.8 (θOS = 0.2231) therefore corresponds to an average change in 
tumour size of 0.10.  In this section we will relate the effect sizes of response and PFS to overall 
survival. 
 
To find the effect in response for a given effect in overall survival, we consider the main criterion 
for partial or complete response as given in RECIST [4] states that a patient is said to have 
responded if a reduction in the sum of diameters of target lesions of at least 30% over baseline is 
achieved.  In our investigation, a patient is therefore classed as having responded if 
(S0 − S8) S0⁄ > 0.3. All other patients, including patients whose tumour size evaluation after 8 
weeks is missing, are considered non-responders.  Note that the definition of response used is a 
slight simplification of the RECIST criteria as it does not incorporate an increase in the number 
of lesions.  This simplification is expected to have little influence on the sample size for a trial 
based on response as the difference between the response rates will likely remain the same. In 
addition no patients with a sufficiently large reduction in tumour size had an increase in the 
number of lesions in the NSCLC dataset so that this simplification did not have an impact on the 
numbers in our example.  
 
Using the above definition, we can estimate the proportion of patients responding on control 
from the data.  To estimate the response rate under the experimental treatment we will use some 
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generated data under the desired effect on overall survival. In particular we start by considering 
the parameter cts which is defined as the expected difference in cts values between the two 
treatments, so that θcts = E{log(1 + S8C) − log(1 + S8E)}, where S8E is the sum of largest 
diameters 8 weeks after start of treatment for a patient in the experimental group and S8C is the 
corresponding quantity for the control group.  The expected tumour size 8 weeks after start of the 
experimental treatment with effect θcts can be found as E(S8E) = exp{log(1 + S8C) − θcts} − 1. 
The response rate under experimental treatment can then be found from the expected week 8 
tumour size by applying the definition of response for each subject and finding the proportion of 
subjects that are expected to respond.   
 
To find an effect size for PFS based on the desired effect in overall survival we use the fact that 
we have already linked the change in tumour size measure to overall survival. The link between 
PFS and cts will be established using a proportional hazards model, using PFS rather than overall 
survival as dependent variable.  The model will use the same covariates as previously but 
parameters will be denoted by γ to reflect that PFS is used instead of overall survival.  Using the 
same arguments as in Section 2 we obtain  
hE(t) = h0(t)e
𝛄′z𝒊+γcts×(cts+θcts) = eγctsθctshC(t), 
and hence the worthwhile treatment effect for PFS in terms of the negative of the log-hazard 
ratio, θPFS, can be expressed in terms of a worthwhile effect in change in tumour size as θPFS =
−γctsθcts.  
 
For the NSCLC dataset this relationship becomes θPFS = 2.3857θcts = (2.3857 2.2159)⁄ θOS. A 
hazard ratio of 0.8 in overall survival therefore corresponds to a change in tumour size of 0.10 as 
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argued previously, and the corresponding hazard ratio for PFS is found as 0.79.  This shows that 
the hazard ratios for progression-free survival and overall survival are empirically quite similar 
and suggests that the effects in terms of PFS and OS should be similar. 
 
To illustrate the relationships of the different effect size measures used in the different trial 
designs some examples are given below.  The change in median overall survival time from 8 
months (the median OS in the dataset) will be taken as the baseline effect size.  The hazard ratio 
is obtained by creating a “pseudo-treatment group” which is an exact copy of the original data 
where OS is shifted by the improvement in median OS.  So for example one month is added to 
the survival times to represent an experimental treatment that increases the median survival time 
from 8 to 9 months.  The original dataset and the artificial dataset are then analysed jointly to 
derive the hazard ratio of 0.8406.  This approach also allows the estimation of the change in 
proportion of patients dying prior to the second assessment of tumour size in the same manner. 
Table 1 provides the effect sizes for different changes in median OS. These effect sizes will 
subsequently be used for sample size comparisons in Section 3.3.   
 
~~~ Table 1 ~~~ 
 
3.3. Sample size requirements 
We now turn to comparing the sample sizes for the different endpoints using the equivalent effect 
sizes derived in the previous section.  For each of the designs the hypotheses H0: θ = θ0 and HA: 
θ > θ0, where θ is the effect parameter for the design, are to be tested. The calculations will be 
made to satisfy the type-I and type-II error constraints, 𝑃(𝑟𝑒𝑗𝑒𝑐𝑡 𝐻0|θ = 0) ≤ 𝛼 and 
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𝑃(𝑟𝑒𝑗𝑒𝑐𝑡 𝐻0|θ = θ1) ≥ 1 − 𝛽, where θ1 is an effect we wish to detect if present. Throughout we 
will denote the 100 η % percentile of the standard normal distribution by zη.  For comparative 
trials we will allow for R:1 randomization between experimental and control treatment and 
denote the total sample size of the trial by n.  
 
The necessary sample size for a trial based on change in tumour size is derived as discussed in 
Section 2.  The sample size and critical value for a single armed trial based on tumour response 
are found by solving  








𝑛−𝑘 ≤ 𝛼 
and 





𝑛−𝑘 ≥ 1 − 𝛽. 
 
Since these inequalities will be satisfied for a number of different combinations of n and u, the 
smallest sample size satisfying the above inequalities will be reported. 
 
For a comparative trial using tumour response, the approximation to a normal distribution is used 





?̅?(1 − ?̅?)(𝑅 + 1)2
𝑅 + 𝑧1−𝛽
√𝑝𝐸(1 − 𝑝𝐸)(𝑅 + 1)
𝑅𝑛 + 𝑝𝐶














For the design of a trial based on progression-free survival, further information such as the 
follow up time of patients is necessary for finding sample sizes.  To avoid additional assumptions 
we will base the design used here on the number of events required.  The sample size will be the 
same as the required number of events if all subjects do progress during the study duration and 
will otherwise be larger.  Under the proportional hazards model and when θPFS is small and the 










as shown in [15]. 
 
Figure 2 compares sample sizes for the different design proposals over a range of improvements 
in median survival time for equal allocation between experimental treatment and control, a type I 
error of 0.1 (one-sided) and a power of 80%.  Tables 2-3 provide the sample sizes for the four 
different design proposals using the effect sizes given in Table 1 above for different type I and 
type II errors.  
~~~ Figure 2 ~~~ 
 
~~~ Table 2 and 3 ~~~ 
 
The results clearly show that a trial based on change in tumour size requires the smallest sample 
size among the alternative approaches for all situations considered.  Moreover, the sample size 
required for a comparative trial based on change in tumour size is very similar to the 
requirements for a single-armed trial based on tumour response even though the latter depends 
on a historical response rate for the control group which may be inaccurate for the patient 
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population under study. Since the required sample sizes for a trial based on change in tumour 
size can be relatively small, the intended type I error rate and power are potentially inaccurate as 
they are based on asymptotic results.  Tables 2 and 3 provide reassurance based on 100,000 
replicate simulation runs. Throughout the tables, the empirical type I error and power are close to 
their nominal levels, indicating the approximations used are satisfactory. 
 
3.4. Sensitivity analysis 
In order to obtain more insight into the relationship between the sample size requirements and to 
investigate the robustness of the conclusions drawn, a sensitivity analysis has been undertaken.  
A key ingredient to our comparison in Section 3.3 is that the relationship between the different 
effect measures has been captured accurately. Consequently we now consider alterations to these 
relationships and investigate the implications for the required sample sizes for the different 
endpoints.  The results shown are based on a hazard ratio for overall survival of 0.8406, a one-
sided type I error of 0.1 and 80% power using a 1:1 allocation.  Other choices of randomization, 
type I error and power have also been studied, but details are omitted as they just confirm the 
patterns shown here. 
 
The first alteration looks at the effect of changing the relationship between overall survival and 
change in tumour size by modifying βcts in Equation (1). Weakening this relationship (moving the 
negative value of βcts closer to 0) means that it is necessary to find a larger effect on change in 
tumour size to anticipate a given effect on overall survival and vice versa.  As the effect sizes for 
PFS and tumour response depend directly on the effect on change in tumour size, the sample 
sizes and the number of events required for the other endpoints will change accordingly (Figure 
3). It is clear from the graph, however, that the order of required sample sizes of the endpoints is 
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maintained although the relative differences change showing that, the required sample sizes for a 
trial based on change in tumour size are smaller than for the alternative designs considered. 
Similarly the required sample size remains comparable to that for a single-arm trial.  
~~~ Figure 3 ~~~ 
 
The second modification looks at the effect of changing the relationship between overall survival 
and progression free survival by modifying γcts. Weakening this link means that information on 
PFS does not contain the same information about overall survival as change in tumour size and 
leads therefore to a smaller effect size to be looked for.  Since this modification has no bearing 
on the effect sizes used for change in tumour size and response, Figure 4 shows unchanged 
sample sizes for all endpoints other than PFS for which the number of events required increase.  
Even changing γcts from the estimated value of 2.3857 to 3.5 does result in a smaller required 
event number than the sample size required for change in tumour size showing that a trial based 
on cts is still more powerful than a trial based on PFS. 
  
~~~ Figure 4 ~~~ 
 
The final modification changed the effect sought in terms of tumour response while keeping all 
other effect sizes constant.  The effect sizes considered are chosen to ensure that only meaningful 
situations are considered (i.e. p1 > p0).  As in the previous situation this adjustment only has 
implications on the sample size required for trials based on tumour response as seen in Figure 5. 
It can be seen that more than doubling the effect size is required to find that the sample size for a 
randomized trial based on tumour response is smaller than for a trial based on change in tumour 
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size, while only small reductions in treatment effect lead to markedly increased sample sizes for 
trials based on tumour response. The conclusions about the merits of using change in tumour size 
therefore appear to be robust.  
~~~ Figure 5 ~~~ 
4. Discussion 
In this manuscript a flexible approach for designing and analysing comparative cancer trials with 
change in tumour size as the primary endpoint, taking account of all information available, has 
been described. The model expressing a normally distributed measure of change in tumour size 
in terms of treatment and other prognostics factors has been related to a model expressing the 
hazard of death to the same set of covariates.  In particular, the parameter representing the 
advantage of the experimental treatment over control in terms of change in tumour size has been 
related to that expressing advantage in terms of overall survival.  This has been achieved through 
the analysis of a pre-existing dataset concerning patients treated in a similar way to the trial of 
interest. One of the key assumptions made is that the effect of treatment on overall survival is 
captured by the effect of treatment on change in tumour size. This implies that, just as in the 
situation when PFS or response rate is used, we are looking at situations in which change in 
tumour size is highly predictive of overall survival.    
The relationships identified are used to compare the sample sizes required for phase II studies 
based on different patient outcomes, under magnitudes of treatment effect that are as far as 
possible consistent with one another.  The approach described is particularly suitable in the 
design of phase II trials, to ensure that the sample size used is sufficient to detect a change in 
tumour size effect that is consistent with the magnitude of hazard ratio that would be of interest 
in a subsequent phase III trial.  The use of historical data to form a link between treatment effects 
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on different endpoints is similar in principle to the approach taken elsewhere for the design of 
stroke trials [16]. 
 
Comparing the sample sizes for the design based on change in tumour size to those for 
alternative phase II designs using equivalent effect sizes shows that the former approach has the 
smallest sample size.  Furthermore it gives sample sizes that are only slightly larger than those 
for a single armed trial based on tumour response. A sensitivity analysis shows that these 
conclusions are highly robust to assumptions made in the derivation of the equivalent effect 
sizes.  
 
Since tumour measurements are already routinely made in order to ascertain response and 
progression-free survival, no change in current practice and no additional data are necessary in 
order to use change in tumour size as the primary endpoint in exploratory studies.  If tumour size 
is assessed regularly, a repeated measure approach could be used, and exploration of this option 
forms the basis of future work. To implement the design approach described here to other 
cancers, it will be necessary to confirm that change in tumour size does indeed translate to an 
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Figure 2: Required sample sizes and number of events for different design proposals for various 
improvements of overall survival time.  Equal randomization between experimental and control, one-
sided type I error is 0.1 and power is 0.8.   
 
  
Set effect size 
as HR for OS 















Figure 1: Schematic overview of comparison. 
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Figure 5: Sample size and number of  events required when altering the effect for response. 









Table 1: Relationships between different effect size measures.  
 
 Target effect size 









8 to 9 months 0.8406 0.0489 0.0784 0.8295 
8 to 10 months 0.7121 0.0889 0.1532 0.6938 
8 to 11 months 0.6054 0.2267 0.2265 0.5826 
 
Table 2: Total sample sizes for different designs and effect sizes with α = 0.1 and 1  β = 0.8 using a 1:1 
randomisation.  
 
θ Response CTS PFS* 
















(.,.)… achieved type I error and power 
[.,.]… empirical type I error and power based on 100,000 simulations 
θ… desired hazard ratio of overall survival times 
* … number of events 
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(.,.)… achieved type I error and power 
[.,.]… empirical type I error and power based on 100,000 simulations 
Θ… desired hazard ratio of overall survival times 
* … number of events 
 
 
